ARQT Stock Ownership Breakdown

A company's 13F filings with the Securities and Exchange Commission (SEC) provides investors with comprehensive information about institutional ownership in a listed company, a sign of strength in terms of how many institutions have confidence in that company. The number of institutional investors who currently own ARQT shares is 264, representing 113.71% of the company's common stock.

TEJARA CAPITAL LTD, in the last quarter, reduced its stake in ARQT by -15.44% restricting it's holding to 940.49 thousand shares of worth nearly $9.32M. MORGAN STANLEY also lessened -34.14% of the ARQT shares from its portfolio, reducing its holding to 4.01 million shares of worth $39.70M. FRANKLIN RESOURCES INC also shunned ARQT shares holding by -0.28% last quarter which brought its holding to 4.64 million shares worth $46.01M.

As per its latest 13F filing, NORTHERN TRUST CORP increased its stake in ARQT by 2.49% in the last quarter. The institutional holder raised its holding to 748.95 thousand shares having worth more than $7.42M. PERCEPTIVE ADVISORS LLC also added 100% more shares of ARQT to its portfolio, raising its holding to 750 thousand shares of worth $7.43M. CHARLES SCHWAB INVESTMENT MANAGEMENT INC also increased its ARQT shares holding by 31.4% which brought its holding to 750.72 thousand shares worth $7.44M.

The insider with the most stakes in ARQT is Heron Patrick J , director at the company. Additionally, ARQT stock is highly held by 10 percent owner Frazier Life Sciences VIII, L.P. and See Remarks Watanabe Todd Franklin among others.

Company executives, directors, and other insiders own 1.93% percent of Arcutis Biotherapeutics, Inc.'s stock. Within the last six months, there have been 18 transaction(s) in which ARQT insiders have sold stock, totaling 163.06K shares. Insiders that have sold shares include WELGUS HOWARD G., BURNETT PATRICK, and WATANABE TODD FRANKLIN.

There have been 3 transaction(s) during the past 6-months in which Arcutis Biotherapeutics, Inc. insiders have bought stock, totalling 4788 shares

Around 5.23M Arcutis Biotherapeutics, Inc. shares are held by insiders, which represents about 1.93% of ARQT stock.

ARQT director, Heron Patrick J holds the largest portfolio of the company's shares. ARQT shares owned by Heron total nearly 8.79 million.

NORTHERN TRUST CORP is the largest institutional owner in ARQT which holds 748.95 thousand shares worth $7.42M or 1.08% of the total ARQT shares outstanding followed by PERCEPTIVE ADVISORS LLC with ownership of 750 thousand shares representing 1.08% of the ARQT ownership. CHARLES SCHWAB INVESTMENT MANAGEMENT INC is the third largest stakeholder with 750.72 thousand shares or 1.08% of the ownership worth more than $7.44M.

Stock options give the owner the ability but not the obligation to buy or sell a security at a predetermined price and date. Stock options can be classified into two types: puts and calls. A put is a bet on falling stock, and a call is a bet on rising stock. As far as the ARQT is concerned, it is a stock which is optionable.

Number of ARQT shares short is 20.97M. Shares short is a market sentiment in which investors have sold their shares short in a given stock but have not yet covered them or closed them out.

As of today, 117.05M shares of ARQT are outstanding.

Float represents the number of tradeable shares in a specific stock. By subtracting restricted and closely-held shares from a firm's total outstanding shares, we can calculate its floating stock. The term "closely-held shares" refers to shares held by employees, major shareholders, and company insiders. At present, ARQT has 85.83M shares in float.

Short ratio is calculated by dividing the number of short shares, short interest or bets that shareholders will sell short from the average daily volume. A higher ratio indicates longer times needed to repurchase borrowed shares (sold). The short ratio for ARQT is 9.95.